Stroke: Pharmacological properties of the novel neuroactive steroid drug NTS-104 and its effect on stroke

In the United States, ischemic stroke affects about 700,000 patients each year, and so far, there are no effective pharmacological preparations that can promote recovery

Experts studied the pharmacodynamics and pharmacokinetics of NTS-104/105 and used models of embolism and transient mid-cerebral artery occlusion to study the dose-related effects

Plasma and brain pharmacokinetic analysis showed that NTS-104 was rapidly converted to NTS-105, reached peak concentrations ≈ 1 hour after the administration, and distributed similarly

One study at a single dose level confirmed that administration of NTS-104 4 hours after transient mid-cerebral artery occlusion also had a neuroprotective effect

In summary, NTS-104 is a novel original drug that can be converted into a novel neuroactive steroid NTS-105, which can improve the functional results

References:

Pharmacological Characterization of a Novel Neuroactive Steroid Prodrug, NTS-104, and Its Neuroprotective Activity in Experimental Stroke Models.